Gorka Fernández-Eulate

Gorka Fernández-Eulate

Auto-generated profile, based on publicly available information

Gorka Fernández-Eulate

AP-HP, Sorbonne Université, Service de Neuromyologie, Centre de référence Nord-Est-Ile-de-France, Institut de Myologie, Hôpital Pitié-Salpêtrière, Paris, France

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 June 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
NANicholas Ashton
Nicholas Ashton
SJShorena Janelidze
Shorena Janelidze
AKAhmad Al Khleifat
Ahmad Al Khleifat
ALAntoine Leuzy
Antoine Leuzy
EEEmma L. van der Ende
Emma L. van der Ende
OHOskar Hansson
Oskar Hansson
Increased cerebrospinal fluid neurofilament light (NfL) is a recognized biomarker for neurodegeneration that can also be assessed in blood. Here, we investigate plasma NfL as a marker of neurodegeneration in 13 neurodegenerative disorders, Down syndrome, depression and cognitively unimpaired controls from two multicenter cohorts: King’s College London (n = 805) and the Swedish BioFINDER study (n = 1,464). Plasma NfL was significantly increased in all cortical neurodegenerative disorders, amyotrophic lateral sclerosis and atypical parkinsonian disorders. We demonstrate that plasma NfL is clinically useful in identifying atypical parkinsonian disorders in patients with parkinsonism, dementia in individuals with Down syndrome, dementia among psychiatric disorders, and frontotemporal dementia in patients with cognitive impairment. Data-driven cut-offs highlighted the fundamental importance of age-related clinical cut-offs for disorders with a younger age of onset. Finally, plasma NfL performs best when applied to indicate no underlying neurodegeneration, with low false positives, in all age-related cut-offs.

23 March 2022 in European Journal of Neurology
Verified
Journal Article
Closed access
DBDanique Beijer
Danique Beijer
MDMaike F. Dohrn
Maike F. Dohrn
JWJonathan De Winter
Jonathan De Winter
SFSarah Fazal
Sarah Fazal
ACAndrea Cortese
Andrea Cortese
JBJonathan Baets
Jonathan Baets

9 February 2022 in Journal of Neurology, Neurosurgery & Psychiatry
Verified
Journal Article
Open access
PDF file
GFGorka Fernández-Eulate
Gorka Fernández-Eulate
CCChristophe Carreau
Christophe Carreau
JBJean-François Benoist
Jean-François Benoist
FLFoudil Lamari
Foudil Lamari
BRBenoit Rucheton
Benoit Rucheton
YNYann Nadjar
Yann Nadjar
Neurometabolic diseases are a group of individually rare but numerous and heterogeneous genetic diseases best known to paediatricians. The more recently reported adult forms may present with phenotypes strikingly different from paediatric ones and may mimic other more common neurological disorders in adults. Furthermore, unlike most neurogenetic diseases, many neurometabolic diseases are treatable, with both conservative and more recent innovative therapeutics. However, the phenotypical complexity of this group of diseases and the growing number of specialised biochemical tools account for a significant diagnostic delay and underdiagnosis. We reviewed all series and case reports of patients with a confirmed neurometabolic disease and a neurological onset after the age of 10 years, with a focus on the 36 treatable ones, and classified these diseases according to their most relevant clinical manifestations. The biochemical diagnostic approach of neurometabolic diseases lays on the use of numerous tests studying a set of metabolites, an enzymatic activity or the function of a given pathway; and therapeutic options aim to restore the enzyme activity or metabolic function, limit the accumulation of toxic substrates or substitute the deficient products. A quick diagnosis of a treatable neurometabolic disease can have a major impact on patients, leading to the stabilisation of the disease and cease of repeated diagnostic investigations, and allowing for familial screening. For the aforementioned, in addition to an exhaustive and clinically meaningful review of these diseases, we propose a simplified diagnostic approach for the neurologist with the aim to help determine when to suspect a neurometabolic disease and how to proceed in a rational manner. We also discuss the place of next-generation sequencing technologies in the diagnostic process, for which deep phenotyping of patients (both clinical and biochemical) is necessary for improving their diagnostic yield.

14 October 2020 in European Journal of Neurology
Verified
Journal Article
Closed access
PDF file
RGRaquel Guimarães‐Costa
Raquel Guimarães‐Costa
GFGorka Fernández‐Eulate
Gorka Fernández‐Eulate
KWKarim Wahbi
Karim Wahbi
FLFrance Leturcq
France Leturcq
EMEdoardo Malfatti
Edoardo Malfatti
TSTanya Stojkovic
Tanya Stojkovic

13 March 2021 in European Journal of Neurology
Verified
Journal Article
Closed access
PDF file
GFGorka Fernández‐Eulate
Gorka Fernández‐Eulate
GQGiorgia Querin
Giorgia Querin
UMUrsula Moore
Ursula Moore
ABAnthony Behin
Anthony Behin
MMMarion Masingue
Marion Masingue
TSTanya Stojkovic
Tanya Stojkovic

1 August 2023 in Neurology Genetics
Verified
Journal Article
Open access
PDF file
GFGorka Fernández-Eulate
Gorka Fernández-Eulate
JTJulian Theuriet
Julian Theuriet
CRChristopher J. Record
Christopher J. Record
GQGiorgia Querin
Giorgia Querin
MMMarion Masingue
Marion Masingue
TSTanya Stojkovic
Tanya Stojkovic
Background and Objectives Spinal muscular atrophy (SMA) is mainly caused by homozygous SMN1 gene deletions on 5q13. Non-5q SMA patients’ series are lacking, and the diagnostic yield of next-generation sequencing (NGS) is largely unknown. The aim of this study was to describe the clinical and genetic landscape of non-5q SMA and evaluate the performance of neuropathy gene panels in these disorders. Methods Description of patients with non-5q SMA followed in the different neuromuscular reference centers in France as well as in London, United Kingdom. Patients without a genetic diagnosis had undergone at least a neuropathy or large neuromuscular gene panel. Results Seventy-one patients from 65 different families were included, mostly sporadic cases (60.6%). At presentation, 21 patients (29.6%) showed exclusive proximal weakness (P-SMA), 35 (49.3%) showed associated distal weakness (PD-SMA), and 15 (21.1%) a scapuloperoneal phenotype (SP-SMA). Thirty-two patients (45.1%) had a genetic diagnosis: BICD2 (n = 9), DYNC1H1 (n = 7), TRPV4 (n = 4), VCP, HSBP1, AR (n = 2), VRK1, DNAJB2, MORC2, ASAH1, HEXB, and unexpectedly, COL6A3 (n = 1). The genetic diagnostic yield was lowest in P-SMA (6/21, 28.6%) compared with PD-SMA (16/35, 45.7%) and SP-SMA (10/15, 66.7%). An earlier disease onset and a family history of the disease or consanguinity were independent predictors of a positive genetic diagnosis. Neuropathy gene panels were performed in 59 patients with a 32.2% diagnostic yield (19/59). In 13 additional patients, a genetic diagnosis was achieved through individual gene sequencing or an alternative neuromuscular NGS. Discussion Non-5q SMA is genetically heterogeneous, and neuropathy gene panels achieve a molecular diagnosis in one-third of the patients. The diagnostic yield can be increased by sequencing of other neuromuscular and neurometabolic genes. Nevertheless, there is an unmet need to cluster these patients to aid in the identification of new genes.